Amneal Reports First Quarter 2024 Financial Results : vimars

‒ Q1 2024 Net Revenue of $659 million; GAAP Net Loss of $92 million; Diluted Loss per Share of $0.30 ‒
‒ Adjusted EBITDA of $152 million; Adjusted Diluted EPS of $0.14 ‒
‒ Company has...

Related Keywords

United States , American , America , Chintu Patel , Amneal Pharmaceuticals Inc , Kashiv Specialty Pharmaceuticals , Exchange Commission , Amneal Group , Drug Administration , Nasdaq , Saol International , Amneal Pharmaceuticals , Co Chief Executive , Nationwide Opioids , Native American Tribal Nations , Full Year , Eastern Time , Investor Relations , Securities Litigation Reform Act , Annual Report , Months Ended March , Cash Flows , Net Loss , Adjusted Net Income , Adjusted Diluted Earnings Per , Adjusted Diluted Earnings , Saol International Limited , Markets ,